

# 33<sup>rd</sup> Conference of ENTIS

8<sup>th</sup>-10<sup>th</sup> September 2022

## BERGAMO, ITALY

Poison Control Center and Teratology Information Service

CENTRO CONGRESSI “GIOVANNI XXIII”



With the collaboration of



Wednesday, 7 September

Conference room 1) Sala Novelli  
2) Sala Stampa  
3) Sala Business

16.00 – 18.30 Board, Scientific and Website Committee Meetings

Thursday, 8 September

Conference room Sala Alabastro

08.00 – 09.30 Registration

### **TRAINING IN TERATOLOGY**

Chair: Orna Diav-Citrin

09.30 – 09.55 The teratogenic risk of caffeine in pregnancy **M. Gallo (20+5 min)**

09.55 – 10.20 Risk communication and scientific misinformation **A. Clavenna (20+5min)**

10.20 – 10.45 Cobalt exposure due to metal-on-metal hip prosthesis in pregnancy: toxicological risks **A. Giampreti (20+5min)**

10.45 – 11.00 *Coffee Break*

Catering room Sala Bianca

### **TRAINING IN TERATOLOGY**

Chair: Wolfgang Paulus & Maria Ellfolk

11.00 – 11.25 Hyperpyrexia as a major teratogen: COVID-19 vaccine implications **S. Običan (20+5 min)**

11.25 – 12.00 Free Discussions

12.00 – 13.30 *Lunch*

Catering room Roof garden

### **ENTIS BUSINESS MEETING**

Chair: Orna Diav-Citrin & Sally Stephens

13.30 – 15.30 *ENTIS business meeting*

15.30 – 16.00 *Coffee Break*

Catering room Sala Bianca

### **MEETING OPENING**

Conference room Sala Alabastro

16.00 – 16.05 Welcome greetings from ENTIS - Official opening **Orna Diav-Citrin**

16.05 – 16.10 Welcome greetings from Bergamo TIS **G. Bacis**

### **SESSION 1 COVID-19 IN PREGNANCY**

Chair: Marco De Santis & Yusuf Cem Kaplan

16.10 – 16.35 Pregnancy and COVID-19 **L. Patanè (20+5 min)**

16.35 – 17.00 COVID-19 vaccines and pregnancy **S. Pirola (20+ 5 min)**

17.00 – 17.25 Breastfeeding and COVID-19 **R. Davanzo (20+5 min)**

17.25 – 18.00 Vaccine uptake among pregnant women: lessons learned and future challenges **B. Cleary (20 min + 15 discussion)**

*End of the first day meeting*

**SESSION 2A CURRENT CONTROVERSIAL ISSUES ON DRUGS IN PREGNANCY***Chair: Jorgos Eleftheriou & Per Damkier*

- 09.00 – 09.25 Introduction to current controversies in teratology: some myths revisited **O. Diav-Citrin (20+5 min)**
- 09.25 – 09.50 Acetaminophen use in pregnancy and ASD & ADHD **Y.C. Kaplan (20+10 min)**
- 09.50 – 10.15 Reprotoxic effects of drugs: differences and similarities between clinical and regulatory approaches **R. Butera (20+5')**
- 10.15 – 10.40 The pathophysiology of neonatal abstinence syndrome due to SSRI **C. Chambers (20+5 min)**

**10.40 – 11.15 Coffee Break, networking and Poster visit***Catering room**Sala Bianca &  
Sala Stucchi***SESSION 2B CURRENT CONTROVERSIAL ISSUES ON DRUGS IN PREGNANCY***Chair: Thierry Vial & Mehmet Zafer Gören*

- 11.15 – 11.40 Ondansetron in pregnancy **P. Damkier (20+5min)**
- 11.40 – 12.05 New pharmacological treatment of opiate addiction in pregnant women **L. Somaini (20+5min)**
- 12.05 – 12.30 NSAID treatment in pregnancy: Risk estimation in the 1st and 2nd/3rd trimester. **K. Dathe (20+5min)**
- 12.30 – 13.15 Panel Discussion on the role of ENTIS in the public debate on controversies of drugs in pregnancy (**Panel: Board and SC Members, 45 min**)

**13.15 – 14.30 Lunch, networking***Catering room**Roof garden***SESSION 2C CURRENT CONTROVERSIAL ISSUES ON DRUGS IN PREGNANCY***Chair: Herbert Juch & Lucie Heringová*

- 14.30 – 15.00 Disease activity assessment of rheumatic diseases and treatment in pregnancy **S. Breda, V. Ramoni (20+5min)**
- 15.00 – 16.30 **FREE COMMUNICATIONS (10+5 min discussion)**
- 15.00 – 15.15 Development and validation of a machine-learning algorithm to predict the relevance of scientific articles in teratology  
**Loes C de Vries**
- 15.15 – 15.30 Potential Sources of Bias in the Analysis of COVID-19 Vaccine Safety during Pregnancy: How the Embryotox study plans to avoid them by design and analysis methods. **Regina Stegherr**
- 15.30 – 15.45 COVID-19 mRNA vaccine in pregnancy: results of the Swiss COVI-PREG registry. **Guillaume Favre**
- 15.45 – 16.00 An overview of the UK COVID-19 Antivirals Pregnancy Registry. **Jonathan Richardson**
- 16.00 – 16.15 Risk of Miscarriage Following Exposure to NSAIDs During Early Pregnancy: A Systematic Review and Meta-Analysis. **Maya Berlin**
- 16.15 – 16.30 Sildenafil and bosentan quantification in human milk: a case report from the ConcePTION project.  
**Michael Ceulemans**

**FRIDAY NIGHT: ENTIS DINNER**

20.00 – 23.30 Taverna dnnd

**SESSION 3 PSYCHOTROPIC DRUGS IN PREGNANCY AND BREASTFEEDING***Chair: Matitahu Berkovitch & Stephanie Padberg*

- 09.00 – 09.25 Antipsychotics in pregnancy: balancing between risks of untreated illness and risks of drug-related adverse effects **U. Albert (20+5min)**
- 09.25 – 09.50 Long-Acting Injectable Antipsychotics use in pregnancy. The Papa Giovanni XXIII Hospital experience **E. Bondi, C. Palumbo (20+5min)**
- 09.50 – 10.15 The pharmacokinetics of antidepressant drugs in breastfeeding **D. Cattaneo (20+5min)**
- 10.15 – 10.40 Neonatal abstinence syndrome: laboratory findings **P. Papa (20+5min)**
- 10.40 – 11.00 Panel Discussion

**11.00 – 12.00** *Coffee Break and Poster visit**Catering room**Sala Bianca & Sala Stucchi***SESSION 4 FREE COMMUNICATIONS AND DEBATES***Conference room**Sala Alabastro**Chair: Ursula Winterfeld & Matteo Cassina*

- 12.00 – 13.00 **FREE COMMUNICATIONS (10+5 min discussion)**
- 12.00 – 12.15 Anti-seizure medication use during pregnancy, trends over time and individual treatment pattern: An Evaluation of the German Embryotox Cohort. **Maria Hoeltzenbein**
- 12.15 – 12.30 Neonatal morbidity after fetal exposure to antipsychotics - a national register-based study. **Aessi Heinonen**
- 12.30 – 12.45 Pregnancy outcome following first-trimester exposure to mirtazapine: an observational comparative cohort study. **S. Shweiki**
- 12.45 – 13.00 Pregnancy outcomes after maternal exposure to trazodone in pregnancy: preliminary results of a comparative ENTIS cohort study. **Kim Dao**
- 13.00 – 13.30 Brief status from the ConCEPTION project

**13.30 CLOSURE****CENTRO CONGRESSI "GIOVANNI XXIII"**

1. Development of a process for collaborative management of the IMI ConcePTION Knowledge Bank - *Alison Olivier*
2. Which elements do we include, and how do we present them, in answers on use of medications during breastfeeding? A descriptive pilot study - *Tina Bakkebo*
3. Use of Prescribed Drugs to Treat Chronic Diseases during Pregnancy in Outpatient Care in Switzerland between 2014 and 2018: Descriptive Analysis of Swiss Health Care Claims Data - *Eva Gerbier*
4. Mental health of pregnant and postpartum women during the third wave of the Covid-19 pandemic. A European cross-sectional study - *Fatima Tauqeer*
5. Open issues in management of carbon monoxide poisoning in pregnancy: practical suggestions - *Georgios Eleftheriou*
6. Can topical NSAIDs be used by pregnant women in the third trimester? - *Gro C Havnen*
7. Why did the Magdalena study- an RCT on the effects on infants born to women with treatment of depression in pregnant women- fail? - *Katarina Wide*
8. Neonatal outcome and adherence to drug therapy in bronchial asthma in pregnancy - *Cecilia Lanzi*
9. Feasibility assessment and validation of the prototype of the Belgian data registration system on medication use during pregnancy and mother-infant outcomes ('BELpREG') - *Laure Sillis*
10. Experiences and perspectives of pharmaceutical industry towards the monitoring of medication safety during pregnancy: a qualitative analysis on a pan-European level - *Laure Sillis*
11. Information needs and preferences of pharmacy staff regarding safe compounding of medicines during pregnancy and lactation: results from a cross-sectional survey in Belgium - *Laure Sillis*
12. Psychomotor development of children exposed to Ondansetron during pregnancy: a prospective cohort study - *Maya Berlin*
13. Neurodevelopmental outcome of children exposed to Selective Serotonin Reuptake inhibitors (SSRI's) or Attention Deficit Hyperactivity Disorder (ADHD) stimulant medications during pregnancy - *Maya Berlin*
14. Pregnancy Outcomes of Favipiravir - *Mine Kadioglu Duman*
15. Evaluation Of Pregnancy Using Mirabegron In Terms Of Teratogenicity - *Mine Kadioglu Duman*
16. Outcomes of 5-Nitroimidazoles Exposure in Pregnancy - *Mine Kadioglu Duman*
17. Outcomes of Olanzapine Exposure in Pregnancy - *Mine Kadioglu Duman*
18. Case Report: Sitagliptin in a Pregnant Woman - *Mine Kadioglu Duman*
19. Queries on medication use during pregnancy: an analysis of data from the Swiss Teratogen Information Service - *Ursula Winterfeld*
20. Renal pathologies and mesalazine use in pregnancy - *M. Zafer Gören*
21. Bilateral renal agenesis following in utero first trimester exposure to gadobutrol - *Ksenia Zagorodnikova*
22. Evolution of the national guidelines on the medicines used to treat COVID-19 in pregnancy: a historical review - *Emeline Maisonneuve*
23. Agomelatine for the treatment of depressive episodes - preliminary data on the use in pregnancy - *Wolfgang Paulus*



## **SPEAKERS**

Albert Umberto, University of Trieste  
Breda Silvia, HPG23, Bergamo  
Butera Raffaella, Toxicon, Pavia  
Caplan Yusuf Cem, Ind. researcher, Berlin  
Cattaneo Dario, Hospital Sacco, Milan  
Chambers Christina, OTIS, USA  
Clavenna Antonio, Mario Negri, Milan  
Cleary Brian, Rotunda Hospital, Dublin  
Damkier Per, Odense, Denmark  
Dathe Katarina, Berlin, Germany  
Davanzo Riccardo, Hospital Burlo, Trieste  
Diav Citrin Orna, Jerusalem, Israel  
Gallo Mariapina, HPG23, Bergamo  
Giampreti Andrea, HPG23, Bergamo  
Običan Sarah, OTIS, USA  
Palumbo Claudia, HPG23, Bergamo  
Papa Pietro, San Matteo, Pavia, Italy  
Patanè Luisa, HPG23, Bergamo  
Pirola Serena, HPG23, Bergamo  
Ramoni Veronique, San Matteo, Pavia  
Somaini Lorenzo, SERD, Biella

Cancellation notice should be sent to ENTIS organizers, and should provide the proof of payment.

§ Any cancellation will be charged a 50€ handling fee.

§ If cancellation occurs before May 31st (end of early registration 300 euro) for any reason, refund will be of 100% of the paid fee (after subtracting the handling fees).

§ If cancellation occurs from June 1st to July 31 (end of regular registration 355 euro) for any reason, refund will be of 50% of the paid fee (after subtracting the handling fees).

### **COVID CANCELLATION:**

In case of Government Authorities prohibit the holding of face to face events due to Covid restrictions, the total amount of registration fee will be refunded to the participant by bank transfer (after subtracting the handling fees)

### **In collaboration with**

**EUROPEAN NETWORK OF TERATOLOGY  
INFORMATION SERVICES**

**ITALIAN SOCIETY  
OF PSYCHIATRY**

**ITALIAN SOCIETY  
OF GYNECOLOGY AND  
OBSTETRICS**

**ITALIAN SOCIETY  
OF TOXICOLOGY**

**ITALIAN SOCIETY  
OF NEONATOLOGY**

## **CONFERENCE LOCATION**

**Centro Congressi Giovanni XXIII  
Viale Papa Giovanni XXIII, 106  
24121 Bergamo**

## **REGISTRATION FOR THE CONGRESS**

Information is available  
on the ENTIS website

## **POSTERS**

Information on poster size and orientation is available on  
the ENTIS website

## **DEADLINE DATES**

Registration opens 1 April, 2022

### **Registration**

**Registration at special rates  
1 April - 31 May 2022 (€ 300)**

**Registration at normal rates  
1 June - 31 July 2022 (€ 355)**

**Registration 1 August to 25 August, the Congress  
Center can accept any registration, asking before by  
email and paying by bank transfer**

**Registration on congress site  
7-9 September 2022 (€ 400)**

**One day Registration  
1 April - 9 September 2022 (€ 150)**

## **ENTIS DINNER**

Included for registered participants  
Accompanying person and one day registration (€ 65)

## **CONTACT**

**Centro Congressi Giovanni XXIII**

**Miss Chiara Vitali**

**Tel. +39 035 236435**

**Fax +39 035 236474**

**e-mail [eventi@centrocongressibergamo.com](mailto:eventi@centrocongressibergamo.com)**

